AstraZeneca PLC (LON:AZN) Insider Michel Demare Buys 2,000 Shares

AstraZeneca PLC (LON:AZN) insider Michel Demare purchased 2,000 shares of the firm’s stock in a transaction on Friday, September 13th. The stock was acquired at an average cost of GBX 118 ($1.56) per share, for a total transaction of £2,360 ($3,117.57).

AstraZeneca Stock Down 0.4 %

LON AZN opened at £119.68 ($158.10) on Wednesday. The business has a 50 day moving average price of £125.80 and a two-hundred day moving average price of £119.19. AstraZeneca PLC has a fifty-two week low of GBX 9,461 ($124.98) and a fifty-two week high of £133.88 ($176.86). The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 84.97. The stock has a market cap of £185.50 billion, a PE ratio of 3,835.90, a P/E/G ratio of 0.93 and a beta of 0.17.

AstraZeneca Cuts Dividend

The company also recently disclosed a dividend, which was paid on Monday, September 9th. Shareholders of record on Thursday, August 8th were issued a GBX 77.60 ($1.03) dividend. The ex-dividend date of this dividend was Thursday, August 8th. This represents a yield of 0.64%. AstraZeneca’s dividend payout ratio is currently 7,500.00%.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. JPMorgan Chase & Co. reissued an “overweight” rating on shares of AstraZeneca in a research report on Monday. Jefferies Financial Group upped their price objective on AstraZeneca from GBX 71 ($0.94) to GBX 74 ($0.98) and gave the stock a “hold” rating in a report on Tuesday, July 2nd. Citigroup reiterated a “buy” rating on shares of AstraZeneca in a report on Tuesday, May 28th. Berenberg Bank restated a “buy” rating and set a £150 ($198.15) price target on shares of AstraZeneca in a research note on Monday, September 2nd. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a £110 ($145.31) price objective on shares of AstraZeneca in a research note on Tuesday, September 3rd. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, AstraZeneca currently has a consensus rating of “Moderate Buy” and an average price target of £105.53 ($139.41).

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.